Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection.

[1]  R. Boulieu,et al.  Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. , 1998, Clinical chemistry.

[2]  N. Winick,et al.  Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Lilleyman,et al.  Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. , 2003, British journal of clinical pharmacology.

[4]  R. D. De Abreu,et al.  Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration. , 1996, Clinical chemistry.

[5]  W. Evans,et al.  Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. , 1995, Molecular pharmacology.

[6]  L. Slørdal,et al.  Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. , 1995, Cancer research.

[7]  J. Bökkerink,et al.  Determination of extracellular and intracellular thiopurines and methylthiopurines with HPLC , 1995 .

[8]  B. Camitta,et al.  Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Lilleyman,et al.  Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia , 1994, The Lancet.

[10]  L. Slørdal,et al.  A high-performance liquid chromatographic method for the determination of 6-thioguanine residues in DNA using precolumn derivatization and fluorescence detection. , 1993, Analytical biochemistry.

[11]  L. Slørdal,et al.  A Sensitive High‐Performance Liquid Chromatographic Method for the Determination of 6‐Mercaptopurine in Plasma Using Precolumn Derivatization and Fluorescence Detection , 1993, Therapeutic drug monitoring.

[12]  T. Matsushita,et al.  Determination of 6‐Mercaptopurine in Acute Lymphoblastic Leukemia Patients' Plasma by High‐Performance Liquid Chromatography , 1991, Therapeutic drug monitoring.

[13]  Y. Kato.  Dose-dependant kinetics of oral 6-mercapopurine in children with leukemia , 1991 .

[14]  G. Rivard,et al.  Isolation of 6-mercaptopurine in human plasma by aluminum ion complexation for high-performance liquid chromatographic analysis. , 1991, Journal of chromatography.

[15]  F. Serre-Debeauvais,et al.  Determination of 6-mercaptopurine and its metabolites in plasma or serum by high performance liquid chromatography. , 1990, Biomedical chromatography : BMC.

[16]  S. Lie,et al.  Pharmacokinetics of Oral 6‐Mercaptopurine: Relationship Between Plasma Levels and Urine Excretion of Parent Drug , 1990, Therapeutic drug monitoring.

[17]  J. Shuster,et al.  Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Schmiegelow,et al.  Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-performance liquid chromatography. , 1989, Scandinavian journal of clinical and laboratory investigation.

[19]  P. V. van Dreal,et al.  HPLC Analysis of 6-Mercaptopurine and Metabolites in Extracellular Body Fluids , 1988, Annals of clinical biochemistry.

[20]  Mark L. Greenberg,et al.  Pharmacokinetic determinants of 6‐mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia , 1986, Clinical pharmacology and therapeutics.

[21]  J. Lilleyman,et al.  Oral 6‐mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations , 1986, Clinical pharmacology and therapeutics.

[22]  A. Zipursky,et al.  Analysis of 6-mercaptopurine in serum or plasma using high performance liquid chromatography. , 1985, Therapeutic drug monitoring.

[23]  J. Grygiel,et al.  Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion. , 1984, Biochemical pharmacology.

[24]  G. J. Dixon,et al.  Activity and Mechanism of Action of 6-Methylthiopurine Ribonucleoside in Cancer Cells Resistant to 6-Mercaptopurine , 1965, Nature.

[25]  F. Bergmann,et al.  The Enzymatic Oxidation of 6-Mercaptopurine to 6-Thiouric Acid1 , 1960 .

[26]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VI. Purines. , 1951, The Journal of biological chemistry.